Chordate Medical Holding AB Logo

Chordate Medical Holding AB

Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.

CMH | ST

Overview

Corporate Details

ISIN(s):
SE0021486131 (+1 more)
LEI:
549300R0GG2J3S0BFN79
Country:
Sweden
Address:
C/O Regus, 164 40 Kista

Description

Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia®, a CE-marked, drug-free neuromodulation treatment. The technology is indicated for the treatment of chronic migraine and chronic rhinitis. Ozilia® provides a non-pharmacological alternative to conventional medications, such as pills or injections, and is associated with minimal side effects. The company's business model is centered on building value through an extensive patent portfolio, clinical studies demonstrating efficacy, and establishing commercial success in selected markets with the goal of a future exit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Chordate Medical Holding AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordate Medical Holding AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordate Medical Holding AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 Tommy Hedberg Other Other 2,917 11,668.00 SEK
2024-03-26 Anders Weilandt Other Buy 800,000 41,440.00 SEK
2024-03-26 Anders Weilandt Other Buy 200,000 10,540.00 SEK
2023-05-26 Anders Weilandt Other Buy 2,000,000 84,000.00 SEK
2023-05-26 Jan Hermansson Other Buy 750,000 31,500.00 SEK
2023-05-26 Nils Henrik Milton Rammer Other Other 350,000 14,700.00 SEK
2023-05-26 Caroline Brandberg Other Other 225,000 9,450.00 SEK
2023-05-26 Tommy Hedberg Other Buy 225,000 9,450.00 SEK
2023-01-09 Anders Weilandt Other Buy 3 2.10 SEK
2022-02-25 Anders Weilandt Other Buy 51,292 3,949,484.00 SEK

Peer Companies

Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom affinity binders for research, diagnostics, and therapeutics.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
United States of America
APVO
Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
A product design and development firm providing services from concept to manufacturing.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
United States of America
ARVN
Asarina Pharma AB Logo
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
An integrated biologics development partner offering services from DNA sequence to cell bank.
South Korea
355690

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.